Experts on a NIH COVID-19 panel have ties to companies involved in coronavirus treatment – IOTW Report

Experts on a NIH COVID-19 panel have ties to companies involved in coronavirus treatment

Eight members of NIH’s COVID-19 Treatment Guidelines Panel list financial ties to Gilead Sciences, whose COVID-19 drug remdesivir has been touted by Dr. Anthony Fauci.

Just The News: Members of the National Institutes of Health’s COVID-19 Treatment Guidelines Panel have financial ties to a company behind clinical trials of a drug to treat coronavirus, as well as to another large pharmaceutical company involved with developing a COVID-19 vaccine.

According to the NIH, members of the panel include U.S. physicians, statisticians, and other experts who are developing treatment guidelines on COVID-19 “intended for healthcare providers.”

A total of eight panel members list a financial relationship with Gilead Sciences on the panel’s Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics document: Judith Aberg, MD, Adaora Adimora, MD, Jason Baker, MD, Roger Bedimo, MD, Eric Daar, MD, David V. Glidden, PhD, Susanna Naggie, MD, and Pablo Tebas, MD.   KEEP READING

6 Comments on Experts on a NIH COVID-19 panel have ties to companies involved in coronavirus treatment

Comments are closed.